ACELYRIN

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch ACELYRIN and buy or sell other stocks, ETFs, and their options commission-free!

About SLRN

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. 

CEO
Mina Kim
CEOMina Kim
Employees
Employees
Headquarters
Agoura Hills, California
HeadquartersAgoura Hills, California
Founded
2020
Founded2020
Employees
Employees

SLRN Key Statistics

Market cap
229.17M
Market cap229.17M
Price-Earnings ratio
-0.84
Price-Earnings ratio-0.84
Dividend yield
Dividend yield
Average volume
Average volume
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$7.25
52 Week high$7.25
52 Week low
$1.85
52 Week low$1.85

Stock Snapshot

ACELYRIN(SLRN) stock is priced at $2.27, giving the company a market capitalization of 229.17M. It carries a P/E multiple of -0.84.

ACELYRIN(SLRN) stock opened on 2026-07-25 at —. The price climbed to — and dipped to —.

The ACELYRIN(SLRN)'s current trading volume is 0.

In the last year, ACELYRIN(SLRN) shares hit a 52-week high of $7.25 and a 52-week low of $1.85.

In the last year, ACELYRIN(SLRN) shares hit a 52-week high of $7.25 and a 52-week low of $1.85.

People also own

Based on the portfolios of people who own SLRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.